“We were one of the first European companies collaborating with TAP. Through TAP, the door opens to some of the top-notch, world-class US clinical centers, which we needed in order to navigate the biology starting from Waldenstroms disease to T cell lymphoma and now AML.”
Tim Van Hauwermeiren, CEO argenx
(Quote from Value Creation for Companies through LLS TAP: Dollars & Beyond, December 2020)
Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) for a live one-hour discussion panel.
Hear from LLS TAP staff and TAP European biotech partners who are dreaming big and making bold progress for blood cancer patients.
12 noon EST/9 am PST
Register to learn more.